Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus

American Journal of Clinical Pathology

Volumn 130, Issue 5, 2008, Pages 745-753

  Van Dekken, Herman ^a,c   Hop, Wim C J ^a   Tilanus, Hugo W ^a   Haringsma, Jelle ^a   Van Der Valk, Hans ^b   Wink, Josiane C ^a   Vissers, Kees J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SINT FRANCISCUS GASTHUIS   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Adenocarcinoma; Barrett esophagus; Biomarker; Dysplasia; Immunohistochemistry

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MYC PROTEIN; PROTEIN P53; SCATTER FACTOR RECEPTOR; SMAD4 PROTEIN; TUMOR MARKER; CTNNB1 PROTEIN, HUMAN; CYCLIN D; CYCLINE;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; DYSPLASIA; ENDOSCOPIC BIOPSY; ESOPHAGEAL ADENOCARCINOMA; EVALUATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; METAPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; BIOSYNTHESIS; DISEASE COURSE; ESOPHAGUS TUMOR; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BETA CATENIN; CYCLINS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 55249090166     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPO31THGVEUIDH     Document Type: Article

References (37)

1. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 1994;25:982-993.
2. Van Dekken H. Histopathology of Barrett's esophagus. In: Tilanus HW, Attwood SEA, eds. Barrett's Esophagus. Dordrecht, the Netherlands: Kluwer Academic Publishers; 2001:159-167.
3. Hage M, Siersema PD, van Dekken H, et al. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol. 2004;39:1175-1179.
4. Corley DA, Levin TR, Habel L, et al. Surveillance and survival in Barrett's adenocarcinoma: a population-based study. Gastroenterology. 2002;122:633-640.
5. Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993;104:510-513.
6. Hameeteman W, Tytgat GNJ, Houthoff HJ, et al. Barrett's oesophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96:1249-1256.
7. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251-255.
8. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368-378.
9. Kerkhof M, van Dekken H, Steyerberg EW, et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology. 2007;50:920-927.
10. Burke AP, Sobin LH, Shekitka KM, et al. Dysplasia of the stomach and Barrett esophagus: a follow-up study. Mod Pathol. 1991;4:336-341.
11. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol. 2001;32:379-388.
12. Cameron AJ, Carpenter HA. Barrett's esophagus, dysplasia and early adenocarcinoma: a pathological study. Am J Gastroenterol. 1997;92:588-591.
13. Dar MS, Goldblum JR, Rice TW, et al. Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy? Gut. 2003;52:486-489.
14. Buttar NS, Wang KK, Lutzke LS, et al. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc. 2001;54:682-688.
15. Weston AP, Sharma P, Topalovski M, et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol. 2000;95:1888-1893.
16. Gray MR, Hall PA, Nash J, et al. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology. 1992;103:1769-1776.
17. Krishnadath KK, Tilanus HW, van Blankenstein M, et al. Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus. Cancer Res. 1995;55:1971-1976.
18. Reid BJ, Sanchez CA, Blount PL, et al. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology. 1993;105:119-129.
19. Menke-Pluymers MBE, Mulder AH, Hop WCJ, et al. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. Gut. 1994;35:1348-1351.
20. Galipeau PC, Cowan DS, Sanchez CA, et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A. 1996;93:7081-7084.
21. Krishnadath KK, Tilanus HW, van Blankenstein M, et al. Accumulation of p53 protein in normal, dysplastic and neoplastic Barrett's esophagus. J Pathol. 1995;175:175-180.
22. Ramel S, Reid BJ, Sanchez CA, et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology. 1992;102:1220-1228.
23. Barrett MT, Sanchez CA, Galipeau PC, et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene. 1996;3:1867-1873.
24. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst. 2000;92:1316-1321.
25. Lao-Sirieix P, Brais R, Lovat L, et al. Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis. Neoplasia. 2004;6:751-760.
26. Bailey T, Biddlestone L, Shepherd N, et al. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol. 1998;152:135-144.
27. Washington K, Chiappori A, Hamilton K, et al. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod Pathol. 1998;11:805-813.
28. Murray L, Sedo A, Scott M, et al. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut. 2006;55:1390-1397.
29. Koppert LB, Wijnhoven BPL, van Dekken H, et al. The molecular biology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:169-190.
30. Barrett MT, Schutte M, Kern SE, et al. Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Cancer Res. 1996;56:4351-4353.
31. Hage M, Siersema PD, Vissers KJ, et al. Molecular evaluation of ablative therapy of Barrett's esophagus. J Pathol. 2005;205:57-64.
32. Van Dekken H, van Marion R, Vissers KJ, et al. Molecular dissection of the chromosome 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin dependent kinase 6 at both genomic and protein expression levels. Genes Chromosomes Cancer. 2008;47:649-656.
33. Hinds PW, Finlay CA, Quartin RS, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ. 1990;1:571-580.
34. Ohbu M, Kobayashi N, Okayasu I. Expression of cell cycle regulatory proteins in the multistep process of oesophageal carcinogenesis: stepwise overexpression of cyclin E and p53, reduction of p21 (WAF1/CIP1) and dysregulation of cyclin D1 and p27 (KIP1). Histopathology. 2001;39:589-596.
35. Symmans PJ, Linehan JM, Brito MJ, et al. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. J Pathol. 1994;173:221-226.
36. Younes M, Lebovitz RM, Lechago LV, et al. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology. 1993;105:1637-1642.
37. Bian YS, Osterheld MC, Bosman FT, et al. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol. 2000;114:583-590.